MedicaidPrior AuthLow impact
Folotyn® (pralatrexate) (New)
Humana·OH · Oncology, Hematology·Medicaid
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicaid Ohio has implemented a new prior authorization policy for Folotyn (pralatrexate) effective January 1, 2026. This IV medication for relapsed or refractory peripheral T-cell lymphoma now requires prior authorization approval demonstrating the specific indication and that the patient hasn't experienced disease progression on this medication.
Action Required
By January 1, 2026: Oncology providers must obtain prior authorization from Humana Medicaid Ohio before prescribing Folotyn (pralatrexate) for peripheral T-cell lymphoma patients. Document that patient has relapsed or refractory PTCL and has not experienced disease progression on Folotyn. Visit www.humana.com/PAL for preauthorization requirements and medical coding information. Claims will be denied without prior authorization.